Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831707 | 1.00 | S1PR5 (0.56) | S1PR5ENPP2HRH3MEN1KMT2A | |
| SCHEMBL16309019 | 1.00 | S1PR5 (0.56) | S1PR5ENPP2HRH3MEN1KMT2A | |
| SCHEMBL11027934 | 0.96 | S1PR5 (0.60) | S1PR5ENPP2HRH3 | |
| SCHEMBL12471153 | 0.96 | S1PR5 (0.60) | S1PR5ENPP2HRH3 | |
| SCHEMBL11027922 | 0.96 | S1PR5 (0.60) | S1PR5ENPP2HRH3 | |
| SCHEMBL11029484 | 0.92 | ENPP2 (0.54) | S1PR5ENPP2 | |
| SCHEMBL1161516 | 0.92 | ENPP2 (0.54) | S1PR5ENPP2 | |
| SCHEMBL21154821 | 0.92 | ENPP2 (0.54) | S1PR5ENPP2 | |
| SCHEMBL1161518 | 0.92 | ENPP2 (0.54) | S1PR5ENPP2 | |
| SCHEMBL11029479 | 0.92 | ENPP2 (0.54) | S1PR5ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660010-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2022-07-27 | — | — | EP | claimed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | claimed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | claimed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | claimed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | claimed |
| US-20180369215-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2018-12-27 | — | — | US | claimed |
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | claimed |
| US-20180028511-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA | 2018-02-01 | — | — | US | claimed |
| US-9808449-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | claimed |
| EP-3150590-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| US-20160263093-A1 | S1P modulating agents | BIOGEN MA INC. | 2016-09-15 | — | — | US | claimed |
| EP-2672823-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2016-08-24 | — | — | EP | claimed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | claimed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | claimed |
| EP-2672823-A1 | S1P MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-2672823-A1 | S1P MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109108-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | S1PR5 5/4885ENPP2 38/4885HRH3 682/4885 |
| US-20140371209-A1 | S1P Modulating Agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 74/4885HRH3 711/4885 |
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 52/4885HRH3 308/4885 |
| US-20180028511-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | S1PR5 5/4885ENPP2 38/4885HRH3 682/4885 |
| US-10406144-B2 | SIP modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 94/4885HRH3 803/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 4/4885ENPP2 56/4885HRH3 309/4885 |
| US-20180369215-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | S1PR5 5/4885ENPP2 38/4885HRH3 682/4885 |
| US-20160263093-A1 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | S1PR5 5/4885ENPP2 38/4885HRH3 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.